- Home
- AEON vs CDIO Comparison
AEON vs CDIO Comparison
Compare AEON & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- CDIO
- Stock Information
- Founded
- AEON N/A
- CDIO 2017
- Country
- AEON United States
- CDIO United States
- Employees
- AEON N/A
- CDIO N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- AEON Health Care
- CDIO Health Care
- Exchange
- AEON Nasdaq
- CDIO Nasdaq
- Market Cap
- AEON 8.0M
- CDIO 6.4M
- IPO Year
- AEON N/A
- CDIO N/A
- Fundamental
- Price
- AEON $0.81
- CDIO $4.46
- Analyst Decision
- AEON Strong Buy
- CDIO Buy
- Analyst Count
- AEON 1
- CDIO 1
- Target Price
- AEON $360.00
- CDIO $60.00
- AVG Volume (30 Days)
- AEON 213.7K
- CDIO 38.4K
- Earning Date
- AEON 08-11-2025
- CDIO 08-11-2025
- Dividend Yield
- AEON N/A
- CDIO N/A
- EPS Growth
- AEON N/A
- CDIO N/A
- EPS
- AEON 117.22
- CDIO N/A
- Revenue
- AEON N/A
- CDIO $19,902.00
- Revenue This Year
- AEON N/A
- CDIO $1,434.82
- Revenue Next Year
- AEON N/A
- CDIO $4,661.91
- P/E Ratio
- AEON $0.01
- CDIO N/A
- Revenue Growth
- AEON N/A
- CDIO N/A
- 52 Week Low
- AEON $0.38
- CDIO $3.22
- 52 Week High
- AEON $269.28
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- AEON 56.89
- CDIO 52.85
- Support Level
- AEON $0.80
- CDIO $3.43
- Resistance Level
- AEON $0.87
- CDIO $4.33
- Average True Range (ATR)
- AEON 0.06
- CDIO 0.29
- MACD
- AEON -0.00
- CDIO 0.22
- Stochastic Oscillator
- AEON 61.23
- CDIO 85.70
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.